A multicentre, phase IIa study of zolbetuximab as a single agent in patients with recurrent or refractory advanced adenocarcinoma of the stomach or lower oesophagus: the MONO study

AbstractBackground. Claudin 18.2 (CLDN18.2) is physiologically confined to gastric mucosa tight junctions; however, upon malignant transformation, perturbation

Bibliographic Details

Main Authors:	Türeci, Özlem (Author) , Sahin, Ugur (Author) , Schulze-Bergkamen, Henning (Author)
Format:	Article (Journal)
Language:	English
Published:	26 June 2019
In:	Annals of oncology Year: 2019, Volume: 30, Issue: 9, Pages: 1487-1495
ISSN:	1569-8041
DOI:	10.1093/annonc/mdz199
Online Access:	Verlag, Volltext: https://doi.org/10.1093/annonc/mdz199 Verlag, Volltext: https://academic.oup.com/annonc/article/30/9/1487/5523176
Author Notes:	O. Türeci, U. Sahin, H. Schulze-Bergkamen, Z. Zvirbule, F. Lordick, D. Koeberle, P. Thuss-Patience, T. Ettrich, D. Arnold, F. Bassermann, S.E. Al-Batran, K. Wiechen, K. Dhaene, D. Maurus, M. Gold, C. Huber, A. Krivoshik, A. Arozullah, J.W. Park, M. Schuler